As we found that elraglusib upregulated tumor cell PD-L1 expression and observed an improvement in survival when elraglusib was combined with anti-PD-L1 therapy as compared to anti-PD-1 therapy, we next looked at PD-L1 staining in the tumor sections (Figure 5G,H). The gene discussed is PDCD1; the disease is neoplasm.